Navigation Links
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
Date:2/5/2008

FRANKLIN, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetes management company, announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the RedChip Small-Cap Investor Conference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm Eastern Standard Time). The conference will be held at the Four Seasons Resort in Scottsdale, Arizona. A live video webcast of the presentation will be available on the RedChip Small-Cap Investor Conference website, http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast and the corresponding presentation will be available on Echo Therapeutics' website shortly following the live presentation.

About Echo Therapeutics

Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and diabetes management company leveraging its expertise in transdermal science to develop and commercialize non-invasive specialty pharmaceutical products and medical devices. Echo's Symphony(TM) CTGM System is a next generation needle- free, wireless, continuous transdermal glucose monitoring (CTGM) system for diabetes home use and emerging hospital critical care markets. Symphony is designed to provide on-demand glucose data conveniently, continuously and cost-effectively. Symphony incorporates Echo's patented feedback mechanism for optimal skin permeation control and its continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings. Echo is also marshalling the potential of its patented AzoneTS(TM) transdermal drug delivery technology to build an extensive pipeline of advanced topical reformulations of FDA-approved products in accordance with the FDA's Section 505(b)(2) guidelines. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead AzoneTS-based product candidate, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's development plans, objectives, expectations and intentions, including, without limitation, statements regarding the Company's Symphony and AzoneTS product candidates. Factors that could adversely affect Echo's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:

Patrick T. Mooney, M.D.

Chairman & CEO

Echo Therapeutics

508-530-0329

Lilian Stern

Stern Investor Relations

212-362-1200


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
2. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Taligen Therapeutics Secures Series B Financing
5. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
9. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 15, 2017 , ... Nanomedical Diagnostics , a cutting-edge ... the launch of the new NHS Agile biosensor chip . The new ... a wide range of molecules, including small and large molecules, peptides, proteins, and ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership ... 2018, at The Roosevelt Hotel in New York City. , “With our experience in ...
(Date:8/14/2017)... ... August 14, 2017 , ... Opal ... using USB or PCI Express, announced the release of SYZYGY™, a new open ... satisfy the need for a compact, low cost, low pin-count, high-performance connectivity solution ...
(Date:8/11/2017)... ... August 11, 2017 , ... Algenist continues to disrupt the ... collagen like never before. , Collagen is the key structural element skin needs ... Liquid Collagen™, which include: , First to market with ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):